Pfizer fixe des objectifs pour l’année prochaine.

0
(0)
Pfizer, one of the world’s leading pharmaceutical companies, has recently announced its projected financial targets for 2024, setting a range for its adjusted earnings per share (EPS) and revenue expectations. The company anticipates its adjusted EPS to fall between $2.05 and $2.25, with revenues projected to range from $58.5 billion to $61.5 billion.

These projections take into account the upcoming completion of the Seagen acquisition, a move that is expected to further strengthen Pfizer’s position in the market. The acquisition of Seagen, a biotechnology company known for its innovative cancer therapies, is seen as a strategic step towards diversifying Pfizer’s portfolio and expanding its presence in the oncology sector.

It is important to note that these financial targets exclude the sales of Pfizer’s Covid-19 products, Comirnaty and Paxlovid. The company foresees an operating sales growth of 8% to 10% when excluding these products, or +3% to 5% if excluding the contribution from Seagen. This indicates that Pfizer’s core business is expected to continue to grow steadily, even without the boost from its Covid-19 products.

In addition to its revenue projections, Pfizer also announced its cost realignment program, which is expected to generate annual net savings of at least $4 billion. This represents an increase of $500 million from the previous target range announced on 1 August, demonstrating Pfizer’s commitment to improving its operational efficiency and reducing costs.

Overall, Pfizer’s financial targets for 2024 reflect the company’s confidence in its ability to deliver strong performance in the coming years. With a focus on strategic acquisitions, continued growth in its core business, and a commitment to cost savings, Pfizer is well-positioned to maintain its leadership in the pharmaceutical industry and drive value for its shareholders.


Notez cet article de 1 à 5 étoile(s).

Note moyenne 0 sur 5. Nombre de notes enregistrées : 0 !

Aucune note pour le moment. Soyez le 1er à noter cette page :)

En savoir plus sur cette actualité ?

Questions les plus fréquemment posées sur cette actualité.

What are Pfizer’s target ranges for its 2024 adjusted EPS?

Pfizer currently expects its adjusted EPS to be in the range of $4.00 to $4.25 by 2024.

What are Pfizer’s projected revenues for 2024?

As of now, Pfizer has not released specific revenue projections for the year 2024. However, the company’s revenue can be influenced by various factors such as market conditions, competition, product launches, and regulatory approvals. It is recommended to consult financial analysts or official sources for the most up-to-date revenue projections for Pfizer in 2024.

How does Pfizer’s acquisition of Seagen impact its projections?

Pfizer’s acquisition of Seagen is expected to have a positive impact on its projections. Seagen is a biotechnology company known for its innovative cancer treatments, and the acquisition will allow Pfizer to expand its portfolio in the oncology space. This acquisition is likely to boost Pfizer’s revenue and earnings growth, as well as strengthen its position in the competitive pharmaceutical market. Additionally, the acquisition of Seagen may also lead to cost synergies and operational efficiencies for Pfizer, further enhancing its financial performance and long-term growth prospects. Overall, the acquisition of Seagen is expected to be a strategic move that will help Pfizer achieve its financial and strategic objectives.

What is Pfizer’s operating sales growth forecast for 2024?

As of now, Pfizer has not provided a specific operating sales growth forecast for 2024. Forecasting future sales growth can be influenced by various factors such as market conditions, competition, regulatory environment, and product pipeline. It is important to note that forecasts can change over time based on new information and developments. Investors and analysts typically rely on the company’s quarterly and annual reports, as well as guidance provided by management, to assess future growth prospects.

What is the expected annual net savings from Pfizer’s cost realignment program?

Pfizer expects to achieve approximately $1.3 billion in annual net savings from its cost realignment program.

Personnes citées

Personnes physiques ou morales citées dans cette actualité.

  • Pfizer: Pfizer is one of the world’s leading pharmaceutical companies. It has recently announced its projected financial targets for 2024, including adjusted earnings per share and revenue expectations. The company is known for its innovative products and strategic acquisitions.
  • Seagen: Seagen is a biotechnology company known for its innovative cancer therapies. Pfizer has announced the acquisition of Seagen, which is expected to further strengthen its position in the market and expand its presence in the oncology sector.

Articles relatifs

Vous avez aimé cet article ? Continuez votre lecture !

Notez cet article de 1 à 5 étoile(s).

Note moyenne 0 sur 5. Nombre de notes enregistrées : 0 !

Aucune note pour le moment. Soyez le 1er à noter cette page :)

0 réponses

Laisser un commentaire

Rejoindre la discussion?
N’hésitez pas à contribuer !

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *